INDIGO Biosciences & Cayman Chemical Sign New Distribution Agreement

State College, PA (February 24, 2014) – INDIGO Biosciences, Inc. today announced it has entered into a distribution agreement with Cayman Chemical Company. Cayman will be promoting and distributing INDIGO’s nuclear receptor assay kits and screening services worldwide. This agreement will position INDIGO to attract more customers, increase their market share and sell its products and services on a global basis.

INDIGO Biosciences is the only contract research services company focused exclusively on nuclear receptor screening, offering a comprehensive menu of nuclear receptor screening services as well as nonhuman nuclear receptor assays, functional assays and custom assay development.

In addition to their on-site contract screening services, INDIGO Biosciences brings their nuclear receptor expertise directly into their client’s lab with easy-to-use assay kits. Each kit includes reporter cells, assay plates and all reagents for both 96 and 384 well formats. Their assay products feature engineered reporter cells prepared using INDIGO’s CryoMite™ process. Once thawed, cells are ready for immediate use and typically present >95% viability. Test compounds may be screened for agonist or antagonist activities against human nuclear receptors expressed within healthy, dividing mammalian cells.

“We are very excited to work with Cayman Chemical,” said Fred Marroni, CEO, of INDIGO Biosciences. “Teaming up with Cayman Chemical will allow us to expand market awareness and service our customers on a global basis.”

“INDIGO Biosciences is a great partner and this agreement supports our mission of supplying scientists worldwide with the research tools necessary for advancing human and animal health. Our real commitment to life science researchers is to offer the highest quality products with affordable pricing,” said Dr. Kirk Maxey, President & CEO, of Cayman Chemical.